GARDP is focused on urgently needed treatments for

drug-resistant bacteria, as well as for the people

worst affected by drug resistance, including children, older adults

and hospitalized patients.

Our Research and development work

Our research and development work in North America and around the world is guided by the GARDP Strategy, which is a five-year road map for developing treatments for drug-resistant infections posing the greatest threat to health and ensuring they are sustainably and responsibly available to every person who needs them. 

GARDP NORTH AMERICA ACTIVITIES ARE FOCUSED ON THREE PILLARS


Research and
development

Our priorities are the development of new antibiotics and sustainable access that includes those most in need – the elderly, the young, and vulnerable populations. GARDP is filling gaps in research and development by tracking, evaluating, and contributing where others are not.


Public health
partnerships

No country, company, or organization can solve the drug resistance crisis alone. GARDP’s success lies in the partnerships we form with governments, the private sector, academia, and civil society. These collaborative relationships are essential to our progress in developing five new treatments for the most critical drug-resistant bacteria in North America and globally.


Sustainable
access

Sustainable access means supplying quality treatments at an affordable price for patients and health systems in a timely and appropriate manner. To ensure the sustainable availability of treatments, we work with our partners to develop innovative solutions that are tailored to specific places, populations, and products.

View our activity report 2020

Research and development pipeline

GARDP’s research and development pipeline outlines our activities and treatment candidates for each of our programs, from discovery work and clinical trials to registration, access, and stewardship.

“Our partnership with GARDP is vital for advancing our intravenous beta-lactam/beta-lactamase inhibitor, cefepime-taniborbactam, from phase 3 clinical trials to approval in order to afford access to patients, including children, who are more susceptible to hard-to-treat bacterial infections.”

- Christopher J. Burns, President and CEO, Venatorx Pharmaceuticals

GARDP is seeking $560 million to support our development of 5 new treatments

We’re developing treatments for drug-resistant infections that pose the greatest threat to global health and economic security.

 

The five new treatments GARDP is developing are focused on drug-resistant bacteria identified by the CDC and WHO as posing the greatest threat to health and development and urgently requiring new antibiotics. This includes developing treatments for babies with sepsis, sexually transmitted infections, and hospital-acquired infections.

Pandemic
Preparedness is key
to prevention

The consequences of not addressing the silent pandemic of drug-resistant infections could result in a future where we are unable to treat common infections like pneumonia, urinary tract infections, and infections in newborns. The COVID-19 pandemic has demonstrated that pandemic preparedness requires a global coordinated effort, and no country can do it alone. Strengthening our ability to fight drug-resistant infections must also ensure affordable access to solutions.